-
CD155/PVR (Extracellular region) Antibody
CD155/PVR (Extracellular region) Antibody
- 中文名称：
- CD155/PVR (Extracellular region) Antibody
- 英文名称：
- CD155/PVR (Extracellular region) Antibody
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA71588
- 规格：
- 0.1 mL|2x0.1 mL|3x0.1 mL|4x0.1 mL|5x0.1 mL
- 保存建议：
- Store at -20 degree C. Stable for 1 year.
- 货期：
- 6-8周
- 来源宿主：
- Mouse
- 反应种属：
- Human
- 应用：
- ICC (Immunocytochemistry), IP (Immunoprecipitation), ELISA, WB (Western Blot)
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:IgG1
克隆号:[M048]
特异性:Clone M048 mouse monoclonal antibody detects a 75kDa* protein on SDS-PAGE "Native" or denatured immunoblots of human A549, NCI-H466, NCI-H1299, MDA-MB-231 and A431 carcinomas. The antibody detects CD155 in the membranes and cytoplasm in NCI-H446 cells after immunocytochemical labeling. The antibody works for western blot, immunoprecipitation, immunocytochemistry, and ELISA capture.
纯度:Protein G chromatography
形式：Mouse monoclonal antibody purified with protein G chromatography is supplied in 100ul phosphate-buffered saline, 50% glycerol, 1mg/ml BSA, and 0.05% sodium azide.
浓度：N/A
- 说明书：
CD155/Poliovirus receptor (PVR)/nectin-like 5 (Necl-5) is a transmembrane glycoprotein with extracellular immunoglobulin like domains, and an intracellular immunoreceptor tyrosine-based inhibitor motif (ITIM). CD155 was originally described as a mediator of poliovirus attachment to cells, but has also been implicated in adherens junction formation. CD155 binds nectin-3, and interacts with integrin alphavbeta3 and PDGFR to regulate integrin clustering and focal contact formation at the leading edge of migrating cells. CD155 is also a ligand for immunoreceptors that regulate tumor surveillance. CD155 binds DNAX-associated molecule 1 (DNAX-1), an activating receptor on natural killer cells and cytotoxic T-cells. Alternatively, CD155 may bind TIGIT immunoreceptor inducing an immunosuppressive and non-cytotoxic profile. In cancers, CD155 expression has been associated with unfavorable prognosis in colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma. Cancer therapies have targeted CD155 interactions with TIGIT, and have used CD155 as a point of entry for recombinant oncolytic polioviruses.
